Cargando…

Cost-effectiveness of continuous erythropoietin receptor activator in anemia

BACKGROUND: Erythropoiesis-stimulating agents (ESAs) are the mainstay of anemia therapy. Continuous erythropoietin receptor activator (CERA) is a highly effective, long-acting ESA developed for once-monthly dosing. A multitude of clinical studies has evaluated the safety and efficiency of this treat...

Descripción completa

Detalles Bibliográficos
Autor principal:	Schmid, Holger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090042/ https://www.ncbi.nlm.nih.gov/pubmed/25050070 http://dx.doi.org/10.2147/CEOR.S46930

Ejemplares similares

Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator)
por: Panchapakesan, Usha, et al.
Publicado: (2007)

Correction of Anemia with Continuous Erythropoietin Receptor Activator in Korean Patients on Long-Term Hemodialysis
por: Oh, Jieun, et al.
Publicado: (2014)

The cost-utility of treating anemia with continuous erythropoietin receptor activator or Epoetin versus routine blood transfusions among chronic hemodialysis patients
por: Maoujoud, Omar, et al.
Publicado: (2016)

Treatment of Anemia in Kidney Disease: Beyond Erythropoietin
por: Wish, Jay B.
Publicado: (2021)

Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study
por: Budde, Klemens, et al.
Publicado: (2014)

Cutaneous leukocytoclastic vasculitis induced by continuous erythropoietin receptor activator
por: Kwon, Hyeok-Jin, et al.
Publicado: (2021)

Erythropoietin in the intensive care unit: beyond treatment of anemia
por: Patel, Nimesh SA, et al.
Publicado: (2011)

Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin
por: Hanna, Ramy M., et al.
Publicado: (2020)

Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report
por: Ikenoue, Tatsuyoshi, et al.
Publicado: (2017)

Efficacy of continuous erythropoietin receptor activator for end-stage renal disease patients with renal anemia before and after peritoneal dialysis initiation
por: Fujimoto, Daisuke, et al.
Publicado: (2020)

A Single Arm Clinical Study on the Effects of Continuous Erythropoietin Receptor Activator Treatment in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia
por: Sezai, Akira, et al.
Publicado: (2023)

Anemia and blood transfusion in the critically ill patient: role of erythropoietin
por: Corwin, Howard L
Publicado: (2004)

Erythropoietin stimulating agents in the management of anemia of chronic kidney disease
por: Hayat, Amir, et al.
Publicado: (2008)

Comparison of Oral Recombinant Erythropoietin and Subcutaneous Recombinant Erythropoietin in Prevention of Anemia of Prematurity
por: Saeidi, R, et al.
Publicado: (2012)

Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor
por: Hernández, Carolina Castillo, et al.
Publicado: (2017)

Erythropoietin and Cancer: The Unintended Consequences of Anemia Correction
por: Debeljak, Nataša, et al.
Publicado: (2014)

Effects of Continuous Erythropoietin Receptor Activator in Sepsis-Induced Acute Kidney Injury and Multi-Organ Dysfunction
por: Rodrigues, Camila E., et al.
Publicado: (2012)

Lipocalin-2, Soluble Transferrin Receptor, and Erythropoietin in Anemia During Mild Renal Dysfunction
por: Nahm, Chung Hyun, et al.
Publicado: (2023)

Erythropoietin Levels in Elderly Patients with Anemia of Unknown Etiology
por: Gowanlock, Zachary, et al.
Publicado: (2016)

Erythropoietin in bone homeostasis—Implications for efficacious anemia therapy
por: Lappin, Katrina M., et al.
Publicado: (2021)

Serum Erythropoietin level in anemia of elderly with unclear etiology
por: Seong, Ju Yong, et al.
Publicado: (2023)

Science review: Recombinant human erythropoietin in critical illness: a role beyond anemia?
por: Coleman, Thomas, et al.
Publicado: (2004)

Alternative Erythropoietin Receptors in the Nervous System
por: Ostrowski, Daniela, et al.
Publicado: (2018)

Scaling Pharmacodynamics from Rats to Humans to Support Erythropoietin and Romiplostim Combination Therapy to Treat Erythropoietin-Resistant Anemia
por: Fan, Xiaoqing, et al.
Publicado: (2023)

The Levels of Hepcidin and Erythropoietin in Pregnant Women with Anemia of Various Geneses
por: Vazenmiller, Dmitriy, et al.
Publicado: (2018)

“Ideal” parathyroid hormone in erythropoietin‐stimulating agents‐resistant anemia
por: Ashraf, Bilal, et al.
Publicado: (2021)

Erythropoietin and Its Angiogenic Activity
por: Kimáková, Patrícia, et al.
Publicado: (2017)

Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma
por: Ribatti, D, et al.
Publicado: (2007)

New insights into erythropoietin and erythropoietin receptor in laryngeal cancer tissue
por: Vukelic, Jelena, et al.
Publicado: (2021)

Regulation of Erythropoietin Receptor Activity in Endothelial Cells by Different Erythropoietin (EPO) Derivatives: An in Vitro Study
por: Trincavelli, Maria Letizia, et al.
Publicado: (2013)

Heart failure-associated anemia: bone marrow dysfunction and response to erythropoietin
por: Ruifrok, Willem-Peter T., et al.
Publicado: (2010)

Tubular immaturity causes erythropoietin-deficiency anemia of prematurity in preterm neonates
por: Asada, Nariaki
Publicado: (2018)

Myelofibrosis-Induced Erythropoietin-Resistant Anemia Due to Severe Refractory Hyperparathyroidism
por: Sethi, Sidharth Kumar, et al.
Publicado: (2018)

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state
por: Joharapurkar, Amit A., et al.
Publicado: (2022)

Gut Microbiota Correlates With Clinical Responsiveness to Erythropoietin in Hemodialysis Patients With Anemia
por: Zhu, Yifan, et al.
Publicado: (2022)

Serum levels of erythropoietin in patients with chronic obstructive pulmonary disease and anemia
por: Rezvani, Alireza, et al.
Publicado: (2023)

Once-monthly continuous erythropoietin receptor activator (CERA) for haemoglobin maintenance in haemodialysis patients with chronic renal anaemia
por: Duman, Neval, et al.
Publicado: (2014)

The Waveform Fluctuation and the Clinical Factors of the Initial and Sustained Erythropoietic Response to Continuous Erythropoietin Receptor Activator in Hemodialysis Patients
por: Liu, Wen-Sheng, et al.
Publicado: (2012)

Successful Treatment of Antibody-mediated Pure Red Cell Aplasia Induced by Continuous Erythropoietin Receptor Activator with Prednisolone
por: Okahashi, Nozomi, et al.
Publicado: (2021)

From Anemia to Erythropoietin Resistance in Head and Neck Squamous Cell Carcinoma Treatment: A Carousel Driven by Hypoxia
por: Lazzari, Grazia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_un2fmaif48qlrq124ohedine7p